CompletedNCT01072630
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity type I
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 91 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 492
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01072630
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBirmingham, United States · Anaheim, United States · Cerritos, United States
78 more locations
- Imperial, United States
- Oceanside, United States
- Pico Rivera, United States
- San Diego, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Stanford, United States
- Temecula, United States
- Washington D.C., United States
- Aventura, United States
- Bradenton, United States
- Jacksonville, United States
- Lauderhill, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Smyrna, United States
- Honolulu, United States
- Oakbrook Terrace, United States
- Park Ridge, United States
- Crestview Hills, United States
- Fall River, United States
- Rochester, United States
- Flowood, United States
- Mount Laurel, United States
- Brooklyn, United States
- New York, United States
- Staten Island, United States
- Beachwood, United States
- Canton, United States
- Oklahoma City, United States
- Portland, United States
- Allentown, United States
- Philadelphia, United States
- Austin, United States
- DeSoto, United States
- Houston, United States
- Irving, United States
- Orem, United States
- Salt Lake City, United States
- Richmond, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- Rosario, Argentina
- Malvern, Australia
- Melbourne, Australia
- Sofia, Bulgaria
- Varna, Bulgaria
- Burgas, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Edmonton, Canada
- Penticton, Canada
- Kingston, Canada
- Mississauga, Canada
- Montreal, Canada
- Dole, France
- Jonzac, France
- Nîmes, France
- Bydgoszcz, Poland
- Gdansk, Poland
- Krakow, Poland
- Cape Town, South Africa
- Centurion, South Africa
- Johannesburg, South Africa
- Paarl, South Africa
- Pretoria, South Africa
- Coslada (Madrid), Spain
- Pamplona, Spain
- Vitoria-Gasteiz, Spain
- Lviv, Ukraine
- S. Oleksandrivka, Ukraine
- Vinnitsa, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
Questions about this study
Who is behind this study?
The study sponsor is Cephalon.
Did this study involve medication?
Yes. The study involved medication, including Armodafinil and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
